| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 08/01/2001 | EP1119563A1 Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) |
| 08/01/2001 | EP1119555A1 Biphenylene lactams as prostaglandin receptor ligands |
| 08/01/2001 | EP1119553A1 Monomeric and dimeric heterocycles, and therapeutic uses thereof |
| 08/01/2001 | EP1119552A1 Ureidopiperidine derivatives as selective human nk 3? receptor antagonists |
| 08/01/2001 | EP1119548A1 Pyrrole-2,5-diones as gsk-3 inhibitors |
| 08/01/2001 | EP1119543A1 N-aralkylaminotetralins as ligands for the neuropeptide y y5 receptor |
| 08/01/2001 | EP1119542A1 Prostaglandin receptor ligands |
| 08/01/2001 | EP1119376A2 Removal of preexisting antibodies to enhance the effectiveness of a therapeutic viral immunogenic agent |
| 08/01/2001 | EP1119372A1 Composition and method for treating allergic diseases |
| 08/01/2001 | EP1119367A1 Method of using fetuin to induce apoptosis in cancer cells |
| 08/01/2001 | EP1119355A1 Naphthalenecarboxamides as tachykinin receptor antagonists |
| 08/01/2001 | EP1119353A1 Compositions and methods of inhibiting neoplastic diseases with compounds related to limocitrin and 5-desmethyl sinensetin |
| 08/01/2001 | EP1119351A2 Use of catechol derivatives as proteinase inhibitors |
| 08/01/2001 | EP1119349A2 Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs |
| 08/01/2001 | EP1119334A1 Two chamber cartridge for atomizers |
| 08/01/2001 | EP1119321A1 Patient temperature regulation method and apparatus |
| 08/01/2001 | EP1119254A1 Novel treatment for stroke management |
| 08/01/2001 | EP1119252A2 Use of melanin for inhibition of angiogenesis and macular degeneration |
| 08/01/2001 | EP1037627B1 Use of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid and of pharmaceutically acceptable salts thereof for the manufacture of a medicament for the treatment of non-allergic ophthalmic inflammatory disorders and for the prevention of ocular neovascularization |
| 08/01/2001 | EP0975350B1 Use of an extract of alchemilla vulgaris |
| 08/01/2001 | EP0877737B1 Novel n-(arylsulphonyl)amino acid derivatives having bradykinin receptor affinity |
| 08/01/2001 | EP0862567B1 5-azabicyclo(3.1.0)hexylalkyl-2-piperidones and -glutarimides as neurokinin receptor antagonists |
| 08/01/2001 | EP0806963B1 Carcinoma treatment |
| 08/01/2001 | EP0777489B1 Low molecular yeast active substance extract and process for preparing the same |
| 08/01/2001 | EP0737074B1 Botulinum toxins for treating hyperhydrosis |
| 08/01/2001 | EP0656946B1 Immunoglobulins devoid of light chains |
| 08/01/2001 | CN1306580A Mumbaistatin, process for its prodn. and its use as pharmaceutical |
| 08/01/2001 | CN1306576A G-beta-gamma regulated phosphatidylinositol-3' kinase |
| 08/01/2001 | CN1306573A Novel human thrombopoietin mutein |
| 08/01/2001 | CN1306541A Compound for unstable dipeptidyl peptidase IV inhibitors |
| 08/01/2001 | CN1306540A Prodrugs of dipeptidyl peptidase IV inhibitors |
| 08/01/2001 | CN1306535A Thienopyridine compounds, their prodn. and use |
| 08/01/2001 | CN1306534A Thienopyrimidines |
| 08/01/2001 | CN1306532A Novel pyrrolo-(3,4-B) quinoline derivatives, method for prodn. and use thereof as medicament |
| 08/01/2001 | CN1306531A Epothilones derivatives, their synthesis and uses |
| 08/01/2001 | CN1306529A Novel form of irbesartan, methods for obtaining said form and pharmaceutical compsns. contg. same |
| 08/01/2001 | CN1306526A Novel heterocyclically substituted amides with cysteine protease-inhibiting effect |
| 08/01/2001 | CN1306511A Novel heterocyclic compounds |
| 08/01/2001 | CN1306509A Substituted benzamides, their prodn. and use as cysteine protease inhibitors |
| 08/01/2001 | CN1306508A Hydroxamic acid derivatives as inhibitors or prodn. of human CD23 and of TNF release |
| 08/01/2001 | CN1306505A Substituted benzamides, their prodn. and use |
| 08/01/2001 | CN1306434A Compsn. for prevention and/or treatment of osteoporosis and alterations due to menopause syndrome |
| 08/01/2001 | CN1306433A Use of chemically-stabilized chlorite solution for inhibiting antigen-specific immune response |
| 08/01/2001 | CN1306431A Compsns. for increasing energy i(in vivo) |
| 08/01/2001 | CN1306427A Acylbenzoxazines for enhancing synaptic response(s) |
| 08/01/2001 | CN1306425A Process for synthesizing Cox-2 inhibitors |
| 08/01/2001 | CN1306424A Utilization of aryl (or heteroaryl) azolylcarbinol derivatives in prepn. of medicament for treatment of neurogenic inflammation |
| 08/01/2001 | CN1306421A Matrix-type transdermal patch for steroid homones |
| 08/01/2001 | CN1305993A Cyclic guanyl preparation used as nitrogen oxide synthetic enzyme inhibitor |
| 08/01/2001 | CN1305989A Benzene sulfonamide compounds, its preparing method and medicinal compsns. contg. same |
| 08/01/2001 | CN1305831A Process for prepairng medicine to treat hernia |
| 08/01/2001 | CN1305815A Hypoglycemic, antihypertensive and antisenility powder for dietotherapy and its preparing process |
| 08/01/2001 | CN1305813A Nail health disinfecting liquid |
| 08/01/2001 | CN1069035C Spirit for face nutrition |
| 07/31/2001 | US6268533 Reacting 4-benzyloxy-3-formamidostyrene oxide with an optically pure 4-methoxy-.alpha.-methyl-n-(phenylmethyl)benzeneethanamine followed by reduction to produce formoterol |
| 07/31/2001 | US6268507 Hydantoin derivatives |
| 07/31/2001 | US6268485 Down-regulation resistant C3 convertase |
| 07/31/2001 | US6268411 Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses |
| 07/31/2001 | US6268398 Aromatic guanidine derivatives |
| 07/31/2001 | US6268397 Alpha-(1-adamantylaminomethyl)3,4-dichlorobenzyl)thioacetamid e and its isomers, as well as the addition salts of these compounds |
| 07/31/2001 | US6268394 Contacting a cell with an amount of a sesquiterpene lactone |
| 07/31/2001 | US6268391 Benzylidene-1,3-dihydro-indol-2-one derivatives a receptor tyrosine kinase inhibitors, particularly of Raf kinases |
| 07/31/2001 | US6268389 Treatment of urinary incontinence by administration of α1L-adrenoceptor agonists |
| 07/31/2001 | US6268387 Inhibitors of the enzyme 15-lipoxygenase and are inhibitors of monocyte chemotaxis. |
| 07/31/2001 | US6268382 Methods and compositions for treating allergic disorders and other disorders using norastemizole in combination with other active ingredients |
| 07/31/2001 | US6268379 Substituted aryl hydroxamic acids as metalloproteinase inhibitors |
| 07/31/2001 | US6268375 10, 11-difluoromethylenedioxycamptothecin compounds with topoisomerase I inhibition |
| 07/31/2001 | US6268369 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines |
| 07/31/2001 | US6268367 Piperazine derivatives for treating bone deficit conditions |
| 07/31/2001 | US6268365 Src family SH2 domain inhibitors |
| 07/31/2001 | US6268363 Antitumor |
| 07/31/2001 | US6268362 Amino anthracyclinone derivatives and their use in the treatment of amyloidosis |
| 07/31/2001 | US6268361 Estrogen dependent disorders including cancer, enodmetriosis, etc |
| 07/31/2001 | US6268352 Promoters of neural regeneration |
| 07/31/2001 | US6268346 Having high biological activity of the same type as the known natural compound bpc, but with shorter amino acid chains. |
| 07/31/2001 | US6268344 Associated with sepsis, purpura fulminans, meningococcal sepsis, bone marrow and other transplantations, severe burns, pregnancy, major surgery, severe trauma, or ards. |
| 07/31/2001 | US6268342 Method of inhibiting fibrosis with a somatostatin agonist |
| 07/31/2001 | US6268337 Methods for treating vascular disorders using activated protein C |
| 07/31/2001 | US6268334 Cells include cardiovascular cells, and the peptide may be delivered in a stent to treat or prevent restinosis. |
| 07/31/2001 | US6268186 By recovering compounds such as lovastatin from a fermentation broth by purifying with an adsorbent resin, extraction using toluene, lactonization, if necessary and washing in toluene with water before isolation |
| 07/31/2001 | US6268180 A nucleic acid encoding a polypeptide; production of biologically active interleukin |
| 07/31/2001 | US6268177 An isolated polynucleotide; therapy and treatment of streptococcal infections, pneumonia, meningitis, sinusitis, conjunctivitis; screening for antibiotics |
| 07/31/2001 | US6268163 Identification of drug candidates modulating factor VII-mediated intracellular signaling |
| 07/31/2001 | US6268138 Retroviral vector capable of transducing the aldehyde dehydrogenase-1 gene and making cells resistant to the chemotherapeutic agent cyclophosphamide and its derivatives and analogs |
| 07/31/2001 | US6267990 Preparation comprising initial dose of ace inhibitor optionally including excipient, first delayed-release pellet, in which active ingredient and optional excipient are covered with coating, second coated delayed-release pellet |
| 07/31/2001 | US6267977 Delivery of hydroxy carboxylic acids |
| 07/31/2001 | US6267972 Cosmetic/pharmaceutical compositions comprising β-adrenergic agonists/substance P antagonists |
| 07/31/2001 | US6267957 Attaching agents to tissue with transglutaminase and a transglutaminase substrate |
| 07/31/2001 | US6267955 Mononuclear phagocytes and their use to promote axonal regeneration |
| 07/31/2001 | US6267952 Lipase inhibiting polymers |
| 07/31/2001 | US6267945 Farnesol-related calcium channel blockers |
| 07/31/2001 | US6267310 Process for separating particles of cohesive material according to size |
| 07/31/2001 | CA2332687A1 Use of prostaglandin (pge2) receptor 4 (ep4) selective agonists for the treatment of acute and chronic renal failure |
| 07/31/2001 | CA2282890C Therapeutic heterocyclic compounds |
| 07/31/2001 | CA2218372C Antagonists of human interleukin-6 that are totally incapable of binding gp 130, and their use in the preparation of pharmaceutical compounds |
| 07/31/2001 | CA2118119C Methods for treating interleukin-1 and tumor necrosis factor mediated diseases |
| 07/31/2001 | CA2072945C Pyrimidine derivatives |
| 07/31/2001 | CA2068763C Use of dibutyl adipate and isopropyl myristate in topical and transdermal products |
| 07/31/2001 | CA2041240C Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds |
| 07/31/2001 | CA1341278C Combination of pyrimidine derivatives and retinoids in separate components to induce and stimulate hair growth and reduce hair loss |